NCT00221039 is a Phase 4 clinical trial of Methoxsalen+ECP in Cutaneous T Cell Lymphoma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00221039?

NCT00221039 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00221039?

Interventions in NCT00221039: Methoxsalen+ECP.

What condition does NCT00221039 study?

NCT00221039 studies Cutaneous T Cell Lymphoma, Mycosis Fungoides.

Is NCT00221039 still recruiting?

NCT00221039 is currently completed. Last updated 17 August 2018.

Last reviewed 2018-08-17 · How we verify

NCT00221039

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

Completed Phase 4 Last updated 17 August 2018

What this trial tests

Phase 4 trial testing Methoxsalen+ECP in Cutaneous T Cell Lymphoma in 7 participants. Completed in 5 April 2011.

Timeline

2 April 2004

Primary endpoint
5 April 2011

5 April 2011

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	2 April 2004
Primary completion	5 April 2011
Estimated completion	5 April 2011
Sites	7 locations across United States

Drugs / interventions tested

Methoxsalen+ECP — full drug profile →

Conditions studied

Cutaneous T Cell Lymphoma — all drugs for Cutaneous T Cell Lymphoma →
Mycosis Fungoides — all drugs for Mycosis Fungoides →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Cutaneous T Cell Lymphoma or Mycosis Fungoides. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study objective is to demonstrate that the UVADEX® Sterile Solution formulation of methoxsalen used in conjunction with the UVAR XTS Photopheresis System can have a clinical effect on the skin manifestations of CTCL (mycosis fungoides) in early stage disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat. · · 2006 · cited 1× · PMID 23074497

Verify or expand the search:

Other recruiting trials for Cutaneous T Cell Lymphoma

Currently open trials in the same condition.

NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
NCT06716658 — JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas · Phase 2 · recruiting
NCT06436677 — A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma · recruiting
NCT05414500 — Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides · Phase 1 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00221039 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 17 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00221039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing